Issue closes on Monday, October 19, 2026, for bidding

Mumbai: The Initial Public Offering of Sahajanand Medical Technologies Limited was subscribed 0.34 times on the first day of bidding, demonstrating strong demand from retail and Qualified Institutional Buyers (QIB) for this IPO.

The issue received bids of 33,58,902 equity shares against the offered 97,50,482 equity shares, according to data available on the stock exchanges.

Qualified Institutional Buyers (QIB) portion subscribed 0.37 times. Non-institutional investors and Retail Portion were subscribed 0.20 times and 0.40 times, respectively. Employee Reserved portion subscribed 0.08 times.

The issue will close for subscription on Monday, October 19, 2026.

A day before the opening of the issue, Sahajanand Medical Technologies Limited had raised Rs 140 crore from anchor investors.

Brokerage houses recommend company
Leading brokerage firms like Anand Rathi, Antique Stock Broking, BP Wealth, GEPL Capital and Ventura Securities have given their “Subscribe” recommendation to Sahajanand Medical Technologies Limited, which is a Class III and Class C/D medical devices company with a portfolio of technologically advanced medical devices across vascular and structural heart intervention.

BP Wealth highlights the company received CE certification in 2020 for its in-house developed biodegradable polymer-based sirolimus-eluting stent, Supraflex Cruz, strengthening its product portfolio in coronary Intervention.

On the valuation front, at the upper price band, the IPO is at a P/E of 53.1 times FY26 earnings, and its specialized product portfolio, established international presence and improving financial performance offer a credible long-term growth opportunity. Recommend “Subscribe”.

GEPL Capital highlights the company’s product portfolio includes coronary stents, coronary balloons, transcatheter aortic valve implantation (TAVI) devices, occluders, renal stents and peripheral drug-coated balloons (DCBs), marketed under flagship brands such as Supraflex Cruz, Cocoon and Hydra.

On the valuation front, at the upper price band, the issue is priced at a P/E of 58 times. The company has reported healthy financial performance, integrated capabilities, healthy market share in DES in India, and growing in international markets. Recommend “Subscribe”.